Eli Lilly's Cancer Revolution: How Loxo Oncology Reshaped an Empire

Deepening Roots: India's Manufacturing Dreams and Global Pharma's Embrace

Eli Lilly's Retatrutide Triumphs in Key Diabetes Trial, Poised to Reshape Obesity Treatment Landscape

Five Crucial Stocks to Watch as We Kick Off the Trading Week

Global Markets Wobble: Asian Shares Reflect Wall Street's AI Stock Rollercoaster

The Final Word: Navigating Pharma's Powerhouse and Gold's Gleam in Today's Markets

Why Barclays Still Sees Eli Lilly as the Undisputed Champion in the Exploding GLP-1 Arena, Even as Rivals Crowd In

Huntsville's Bold Bet: Unpacking the Multi-Billion-Dollar Eli Lilly Investment

Wegovy in Vials? Novo Nordisk's Strategic Shift to Boost Supply and Challenge Eli Lilly

The Weight-Loss Drug Wars: Novo Nordisk Eyes Vials for Wegovy in High-Stakes Battle

GLP-1 Medications: Separating Hype from Health with Expert Insights

Eli Lilly's Ascendant Journey: Why Its Premium Price Tag Might Just Be Worth It

Novo Nordisk: The High-Stakes Balancing Act Between Price and Scale

The Market's Two Minds: Lilly's High-Stakes Game Meets Housing's Quiet Comeback

Eli Lilly CEO Sees Medicare Support as Game-Changer for New Oral Obesity Pill

A New Era in Obesity Treatment: The Rise of Oral Weight-Loss Solutions

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

Navigating the Complex Currents of Modern Pharmaceuticals

A Collective Sigh of Relief: Eli Lilly Breaks Nine-Day Losing Streak

The Great Unbundling: Why Weight Loss Drug Prices Are Finally Coming Down

Eli Lilly's Jaypirca Secures Full FDA Approval, Offering New Hope for Certain Blood Cancers

Eli Lilly's Zepbound Gets a Significant Price Drop: What It Means for Patients and the Market

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

Eli Lilly Slashes Zepbound Prices Amid Political Pressure and Trump's Claims

The Next Frontier: Unpacking 'Ozempic 2.0' and the Future of Weight Management

Unanimous Picks: Why Top Funds Are Doubling Down on These Six Stocks

A New Era for Weight Loss: The Revolution of GLP-1 Pills and Monthly Shots

Modern Health's Crossroads: Unpacking Ultra-Processed Food Warnings and the Egg Freezing Debate

Eli Lilly's Trillion-Dollar Triumph: Reshaping the Pharma Landscape

The Trillion-Dollar Bet: How Eli Lilly is Reshaping the Global Economy

Eli Lilly's Trillion-Dollar Triumph: A New Chapter in Pharmaceutical History

The Pharma Giants' Bold Leap: Novo Nordisk and Eli Lilly Eyeing Direct Sales of Obesity Drugs to Employers

Wegovy's Reckoning: Novo Nordisk's CEO Digs In as the Weight Loss Market Heats Up

The Pharmaceutical Reckoning: How Weight Loss Breakthroughs Are Rewriting the Rules, One Pill (or Shot) at a Time

The $1,000 Question: Where Savvy Investors Are Parking Their Money for Tomorrow's Gains

Julianne Moore's Enduring Crusade: Beyond the Screen, Forging a Path to Brain Health

A Glimmer of Hope: Eli Lilly's Bold Leap into Gene Therapy for Blinding Eye Diseases

The GLP-1 Gold Rush: Will Trump Rewrite the Rules for Eli Lilly and Novo Nordisk?

The Billion-Dollar Battle for the Future of Weight Loss: Pfizer Jumps into the Ring